Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd (GUJTHEM) last reported results for the quarter ended Jun 2026, with sales of ₹44 crore and net profit of ₹11 crore. The stock last traded at ₹364, a market capitalisation of ₹4,733 crore, on a P/E of 97.2. Over the past 52 weeks the stock has ranged between ₹225 and ₹479. Figures are as of 9 Oct 2026 and are not real time.
Gujarat Themis Biosyn Ltd share price and key metrics
- Current price
- ₹364
- Market cap
- ₹4,733 cr
- Stock P/E
- 97.2
- ROE
- %
- ROCE
- %
- Dividend yield
- 0.18%
- 52w high / low
- 479/225
Metrics as of 9 Oct 2026. Not real time.
Track Gujarat Themis Biosyn Ltd
Cruxal reads every Gujarat Themis Biosyn Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Gujarat Themis Biosyn Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- 47%
- 5 Years
- 37%
- 3 Years
- 34%
- 1 Year
- -13%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Gujarat Themis Biosyn Ltd quarterly results
| ₹ crore | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 36 | 44 | 44 |
| Expenses | 22 | 25 | 23 |
| Operating profit | 14 | 19 | 21 |
| OPM % | 39% | 44% | 48% |
| Other income | 0 | 1 | 0 |
| Interest | 0 | 2 | 2 |
| Depreciation | 2 | 4 | 4 |
| Profit before tax | 12 | 14 | 15 |
| Tax % | 25% | 24% | 27% |
| Net profit | 9 | 11 | 11 |
| EPS (₹) | 0.83 | 1.00 | 1.02 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gujarat Themis Biosyn Ltd annual results
| ₹ crore | Mar 2026 |
|---|---|
| Sales | 166 |
| Operating profit | 76 |
| OPM % | 46% |
| Net profit | 47 |
| EPS (₹) | 4.28 |
TTM is the trailing twelve months to the most recent quarter.
Gujarat Themis Biosyn Ltd shareholding pattern
Promoters held 59.33% at Aug 2026, down from 70.87% at Sep 2025. FIIs 4.93% and DIIs 13.79%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.87% | 70.87% | 70.87% | 70.87% | 70.87% | 70.86% | 70.87% | 59.33% |
| FIIs | 1.42% | 1.91% | 2.51% | 2.95% | 1.96% | 1.80% | 1.76% | 4.93% |
| DIIs | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 1.17% | 13.79% |
| Public | 26.55% | 26.05% | 25.44% | 25.01% | 26.00% | 26.15% | 26.18% | 21.95% |
| No. of shareholders | 30,934 | 30,673 | 28,945 | 28,319 | 27,325 | 26,886 | 27,010 | 26,899 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd corporate filings
- Gujarat Themis Biosyn Limited's AGM Voting Results Indicate Strong Shareholder Support for Key ResolutionsAGM/EGMhigh impact
Cruxal's analysis: Gujarat Themis Biosyn Limited held its 45th AGM on 30th September 2026, with detailed…
Read the full analysis - Themis Medicare Limited shareholder approval for multiple resolutions including AGM, director reappointment, dividend declaration, remuneration ratification, and amendments to Articles of Association, all passed with overwhelming majority.AGM/EGMlow impact
Cruxal's analysis: Themis Medicare Limited has successfully obtained shareholder approval for key…
Read the full analysis - Gujarat Themis Biosyn Limited's AGM results indicate strong shareholder approval for key resolutions, with over 99% voting in favor on all major items, including financial adoption, director reappointment, dividend declaration, and related-party transactions. The company’s voting patterns show near-unanimous support, reflecting positive investor sentiment and confidence in management decisions. The resolutions related to financial statements, director reappointment, dividend payout, and strategic funding measures received overwhelming approval, suggesting stability and shareholder backing for upcoming growth initiatives.AGM/EGMhigh impact
Cruxal's analysis: Gujarat Themis Biosyn Limited reported near-unanimous shareholder approval for all…
Read the full analysis - Gujarat Themis Biosyn Limited conducts 45th AGM; no new financial disclosures or strategic announcements madeAGM/EGMlow impact
Cruxal's analysis: Gujarat Themis Biosyn Limited held its 45th AGM on 30th September 2026, with proceedings…
Read the full analysis - Gujarat Themis Biosyn Ltd amends Memorandum & Articles of Association as per Regulation 30Company Updatelow impact
Cruxal's analysis: The company has issued an intimation regarding amendments to its Memorandum and Articles…
Read the full analysis - Gujarat Themis Biosyn Limited conducts 45th AGM; no immediate financial disclosures or strategic updates announcedAGM/EGMlow impact
Cruxal's analysis: Gujarat Themis Biosyn Limited held its 45th Annual General Meeting on 30th September…
Read the full analysis - Kindly refer to the intimation of trading window closure.Insider Trading / SASTlow impact
- Gujarat Themis Biosyn Ltd issues corrigendum to 45th Annual General Meeting noticeCompany Updatelow impact
Cruxal's analysis: The company has published a corrigendum regarding the notice for its 45th Annual General…
Read the full analysis - Gujarat Themis Biosyn Limited issues corrigendum to AGM notice regarding INR 335.00 crore preferential issueAGM/EGMmedium impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has issued a corrigendum to its 45th AGM notice to rectify…
Read the full analysis - Gujarat Themis Biosyn Limited fixes September 23, 2026, as record date for final dividend for FY 2025-26Corp. Actionlow impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has officially announced Wednesday, September 23, 2026, as…
Read the full analysis - Gujarat Themis Biosyn Limited completes acquisition of Japan-based MicroBiopharm Japan Co., Ltd. for JPY 21.5 billionCompany Updatehigh impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has finalized the 100% acquisition of Japan-based…
Read the full analysis - Gujarat Themis Biosyn Ltd announces allotment of securities under Regulation 30Company Updatelow impact
Cruxal's analysis: Gujarat Themis Biosyn Ltd has filed a disclosure regarding the allotment of securities…
Read the full analysis - Gujarat Themis Biosyn Limited approves private placement of Non-Convertible Debentures up to INR 585 croreBoard Meetinghigh impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has announced board approval for the issuance of…
Read the full analysis - Gujarat Themis Biosyn Limited Proposes Amendment to Articles of Association to Broaden Financial Institution DefinitionAGM/EGMlow impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has issued an addendum to its 45th Annual General Meeting…
Read the full analysis - Gujarat Themis Biosyn Limited to consider fund raising via Non-Convertible Debentures on 10th September 2026Board Meetingmedium impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has announced a board meeting scheduled for 10th September…
Read the full analysis - Gujarat Themis Biosyn Limited Announces 45th Annual General Meeting and Book Closure DatesCompany Updatelow impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has scheduled its 45th Annual General Meeting for September…
Read the full analysis - Gujarat Themis Biosyn Limited reports passive promoter stake dilution following 2.12 crore share QIP allotmentInsider Trading / SASTmedium impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has undergone a change in shareholding structure due to the…
Read the full analysis - Gujarat Themis Biosyn Limited Announces Preferential Issue of Equity Shares Aggregating 335.00 croreBoard Meetinghigh impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has approved a preferential issue of 82.11 lakh equity…
Read the full analysis - Gujarat Themis Biosyn Limited successfully raises 750 crore via Qualified Institutions Placement (QIP)Company Updatehigh impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has successfully concluded its Qualified Institutions…
Read the full analysis - Gujarat Themis Biosyn Limited successfully concludes QIP, raising approximately 750.00 crore via issuance of 2.12 crore equity sharesCompany Updatehigh impact
Cruxal's analysis: Gujarat Themis Biosyn Limited has successfully closed its Qualified Institutions…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.